PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-1.81
Negative P/E while CRVO shows 0.00. Joel Greenblatt would examine path to profitability versus competitor.
No Data
No Data available this quarter, please select a different quarter.
2.70
P/B of 2.70 while CRVO has zero book value. Bruce Berkowitz would examine asset quality advantage.
-11.40
Negative FCF while CRVO shows P/FCF of 0.00. Joel Greenblatt would examine cash flow improvement potential.
-11.45
Negative operating cash flow while CRVO shows P/OCF of 0.00. Joel Greenblatt would examine operational improvement potential.
2.70
Fair value ratio of 2.70 while CRVO has zero value. Bruce Berkowitz would examine valuation methodology.
-13.79%
Earnings yield 7-10% - Fair value range. Seth Klarman would verify if yield provides sufficient margin of safety. Check Operating Margins.
-8.77%
Negative FCF while CRVO shows yield of 0.00%. Joel Greenblatt would examine cash flow improvement potential.